Non Hodgkin Lymphoma Clinical Trial
Long-term Cognitive, Neuropsychiatric and Functional Outcomes in Adults Who Have Received Chimeric Antigen-Receptor T-Cell (CAR-T) Therapy for Aggressive Lymphoma at Stanford
Summary
This study aims to assess the feasibility of performing neuropsychological testing to measure the cognitive performance of individuals following Axicabtagene ciloleucel CAR-T therapy at Stanford.
Eligibility Criteria
Inclusion Criteria:
>/= 18 years-old
Treated with Axicabtagene ciloleucel CAR-T therapy at Stanford Or
Treated with standard commercial Axicabtagene ciloleucel CAR-T therapy elsewhere and followed primarily by SHC Blood and Bone Marrow transplant providers
>/= 6 months from the date of CAR-T infusion
Fluent in English
Able to attend and participate in in-person testing (Arm I)
Able to participate in remote video testing with adequate workspace, computer and internet capabilities for a reliable telehealth video connection (Arm II)
Exclusion Criteria:
Concurrent enrollment in a CAR-T therapeutics research study
Unable to be present for the scheduled testing
Unable to participate in testing due to severe cognitive or physical limitation
Actively receiving chemotherapy
Progressive cancer
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
San Francisco California, 94305, United States More Info
Sub-Investigator
Sub-Investigator
Sub-Investigator
Sub-Investigator
Sub-Investigator
How clear is this clinincal trial information?